Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
| Revenue (TTM) | $2.23B |
| Gross Profit (TTM) | $-1.47B |
| EBITDA | $-2.20B |
| Operating Margin | -558.00% |
| Return on Equity | -39.00% |
| Return on Assets | -13.30% |
| Revenue/Share (TTM) | $5.66 |
| Book Value | $16.95 |
| Price-to-Book | 3.74 |
| Price-to-Sales (TTM) | 11.55 |
| EV/Revenue | 9.7 |
| EV/EBITDA | 4.64 |
| Quarterly Earnings Growth (YoY) | -85.10% |
| Quarterly Revenue Growth (YoY) | 2.10% |
| Shares Outstanding | $399.24M |
| Float | $372.27M |
| % Insiders | 7.32% |
| % Institutions | 80.41% |
Volatility is currently contracting
MRNA keeps its 2026 growth target intact while cutting cost guidance and advancing flu, oncology and rare-disease programs toward key milestones.
Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.
The Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic, said the manufacturer, Moderna.The shot, named mFlusiva, is intended for adults who are 50 and older. Other brands of flu shots already have begun arriving in pharmacies ahead of fall vaccination season, and Moderna said late Wednesday that it expects some of its new version to be available soon at select retailers.While there already are multiple flu vaccine options in the U.S., including three specifically recommended for people age 65 or older, tens of thousands of Americans die from influenza every year and older adults are among the most vulnerable.Flu vaccines must be updated annually to best match circulating strains of the virus.
Moderna (MRNA) stock made a name for itself during the height of the pandemic, trading as high as $497 five years ago in 2021. Now, shares of the drugmaker sit at $55.12, pivoting lower despite the Food and Drug Administration (FDA) approving the company's flu vaccine.
Moderna Inc (NASDAQ:MRNA) is up 3.6% at $58.30 ahead of the open, after the U.S. Food and Drug Administration (FDA) approved the company's mRNA-based seasonal flu vaccine , mFluvis, for adults ages 50 and older.
Memory stocks falter after guidance from Sandisk and Western Digital fails to meet the market's sky-high expectations.
"Flu remains a significant public health challenge, and mFLUSIVA provides an important new option for America's seniors. This approval also reflects the ongoing potential of our mRNA platform,” Moderna CEO Stéphane Bancel said.
Moderna's vaccine candidate targets a species of ebolavirus behind a deadly outbreak in the Democratic Republic of the Congo.
Moderna on Tuesday said it has begun its first human trial of an experimental vaccine to protect against Bundibugyo ebolavirus, a strain of Ebola that has killed more than 1,650 people so far and currently has no approved vaccine.
Phase 1 trial will evaluate safety and immune response for a strain of Ebola virus disease with no licensed vaccines indicated Phase 1 trial is being conducted in Canada as part of our expanded collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI), building on Moderna's prior filovirus research CAMBRIDGE, MA / ACCESS Newswire / August 4, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that following Health Canada's authorization of the study, the first participants have been vaccinated in a Phase 1 clinical study in Canada evaluating mRNA-1469, the Company's investigational mRNA vaccine being evaluated to prevent Bundibugyo ebolavirus, or BDBV, disease. The vaccine candidate is being developed using Moderna's mRNA platform, the same technology that demonstrated rapid development, scalability, and global deployment capabilities during the COVID-19 pandemic.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MRNA and any ticker you trade — then tracks every position and per-strategy win rate.
